ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bone density"

  • Abstract Number: 2136 • ACR Convergence 2024

    Distal Radius Correlation with Femur and Lumbar Spine T-scores: A Comprehensive Analysis

    Monder Lafi1, Hamzah Amin2, Muhammed Aqib Khan3 and Marwan Bukhari4, 1LANCASTER UNIVERSITY, Liverpool, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3Lancaster Medical School, Lancaster, United Kingdom, 4University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom

    Background/Purpose: Osteoporosis, defined by the WHO as a BMD reduction of 2.5 standard deviations below that of a young healthy adult, is a major public…
  • Abstract Number: 0030 • ACR Convergence 2024

    The Impact of Treadmill Exercise on Various Stages of Osteoarthritis Progression in a Murine Osteoarthritis Model

    Mengcun Chen1, Mingshu Cui2, Yangmei Yang3 and Bin Wang1, 1Thomas Jefferson University, Philadelphia, PA, 2Thomas Jefferson University, Philadelpha, 3Thomas Jefferson University, Philadephia

    Background/Purpose: Evidence supports the benefits of exercise on joint health and its protective effects against osteoarthritis (OA) progression [Allen J, A&R, 2010]. However, most animal…
  • Abstract Number: 2141 • ACR Convergence 2024

    Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis

    Marlene Marte Furment1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY, Syracuse, NY

    Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…
  • Abstract Number: 0415 • ACR Convergence 2024

    Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis

    narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
  • Abstract Number: 2142 • ACR Convergence 2024

    Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis

    KEN NAKASEKO, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan

    Background/Purpose: Osteoporosis is often diagnosed based on bone mineral density (BMD) measurements at the hip or lumbar spine. However, our previous study reported that 38%…
  • Abstract Number: 1029 • ACR Convergence 2024

    An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network

    Benjamin Wolff1, Ryan Bigelsen2, Kathryn Zaffiri2, Susan Kim3 and Philip Dunn4, 1Lehigh Valley Health Network, Macungie, PA, 2Lehigh Valley Health Network, Allentown, PA, 3Lehigh Valley Hospital Network, Allentown, PA, 4Lehigh Valley Health Network, Emmaus, PA

    Background/Purpose: Osteoporosis is a widely recognized disease of the bone where bone mineral density is decreased leading to increased risk for fracture. Bone mineral density…
  • Abstract Number: 2143 • ACR Convergence 2024

    Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population

    Marina soledad Moreno Garcia1, Roxana González Mazario2, yedra uson Rodriguez3, Erardo meriño Ibarra4, Emilio Giner5, Juan Carlos Cobeta García6, Marilia Arce Benavente7, maria Dolores Fábregas canales8, Julia Ullier Bellmunt3, Giuliano Boselli3, pilar martinez Valles7, Jorge Juan Fragío Gil9, carlos Vazquez Galeano7 and Ana Turrion Nieves10, 1hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, 2Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, 3hospital miguel servet, zaragoza, Aragon, Spain, 4Hospital San Jorge Huesca, zaragoza, 5Hospital Royo Villanova, Teruel, Spain, 6Hospital Ernest Lluch, zaragoza, 7hospital miguel servet, Zaragoza, 8Hospital de Barbastro, Huesca, Spain, 9Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, 10Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain

    Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
  • Abstract Number: 0860 • ACR Convergence 2023

    Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation

    Chandramohan Natarajan1, Julia Lucchino1, David Chenoff2 and Yaakov Levine1, 1SetPoint Medical, Valencia, CA, 2SetPoint Medical, Sausalito, CA

    Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
  • Abstract Number: 1185 • ACR Convergence 2023

    Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients

    Tine Vanhaverbeke1, Dirk Elewaut2 and Ruth Wittoek1, 1Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, 2Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: In osteoporotic patients, discontinuation of denosumab is associated with a rapid increase in bone turnover and bone loss. Denosumab was recently proven to have…
  • Abstract Number: 1996 • ACR Convergence 2023

    Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics

    Karla Miller1, Melissa Steffen2, Kimberly McCoy2, Michelle Mengeling2, Heather Davila2, Shylo Wardyn2 and Samantha Solimeo2, 1University of Utah School of Medicine, Salt Lake City, UT, 2Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA

    Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
  • Abstract Number: 1997 • ACR Convergence 2023

    A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis

    Richard Eastell1, Bente Langdahl2, Yoon-Sok Chung3, Rafal Plebanski4, Edward Czerwinski5, Eva Dokoupilova6, Jerzy Supronik7, Jan Rosa8, Anna Rowińska-Osuch9, Ki-Hyun Baek10, Audrone Urboniene11, Sohui Ahn12, Younghee Rho12 and Jisuk Ban12, 1University of Sheffield, Sheffield, United Kingdom, 2Aarhus University Hospital, Aarhus, Denmark, 3Ajou University Hospital, Suwon, South Korea, 4Klinika Zdrowej Kosci, Łódź, Poland, 5Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, 6Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, 7OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, 8Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, 9ETG Warszawa, Warszawa, Poland, 10Yeouido ST. Mary's Hospital, Seoul, South Korea, 11JSC Saules seimos medicinos centras, Kaunas, Lithuania, 12Samsung Bioepis, Incheon, South Korea

    Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
  • Abstract Number: 2000 • ACR Convergence 2023

    Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study

    Mai Kawazoe1, Kaichi Kaneko2, Shotaro Masuoka3, Soichi yamada3, Zento Yamada3, Sei Muraoka3, Karin Furukawa1, Hiroshi Sato3, Eri Watanabe3, Keiko Koshiba3, Izumi Irita3, Miwa Kanaji3 and Toshihiro Nanki1, 1Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, 2Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, 3Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…
  • Abstract Number: 2003 • ACR Convergence 2023

    Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis

    Ruban Dhaliwal1, John Boxberger2, Yamei Wang2, Bruce Mitlak2, Ludovic Humbert3 and Neil Binkley4, 1Massachusetts General Hospital, Boston, MA, 2Radius Health, Inc., Boston, MA, 33D-Shaper Medical, Barcelona, Spain, 4University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI

    Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…
  • Abstract Number: 2007 • ACR Convergence 2023

    Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

    Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
  • Abstract Number: 2011 • ACR Convergence 2023

    Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis

    Nicholas Rossi1, Aamir Saeed2, Aqib Khan3, Hamzah Amin2, Ummaz Nadeem2, Zain Sultan3 and Marwan Bukhari2, 1University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom

    Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology